TET1
Overview
TET1 is a dioxygenase that oxidizes 5-methylcytosine to drive DNA demethylation. In the corpus, TET1 is among the recurrent SNVs identified in anaplastic thyroid carcinoma (ATC).
Alterations observed in the corpus
- TET1 was identified as a recurrent SNV by SeqSig analysis in anaplastic thyroid carcinoma across a comprehensive genomic and evolutionary landscape study of ATC PMID:38412093.
- Downregulated expression in Cluster 1 cholangiocarcinoma, suggesting loss-of-demethylation as an epigenetic mechanism for Cluster 1 hypermethylation PMID:28667006
Cancer types (linked)
- THPA — recurrent SNV in ATC identified by SeqSig analysis PMID:38412093.
Co-occurrence and mutual exclusivity
- TET1 mutations co-occur with other ATC drivers (TP53, BRAF V600E, CDKN2A deletions) in the ATC genomic landscape PMID:38412093.
Therapeutic relevance
- No direct targeted therapy reported in the corpus.
Open questions
- Frequency and functional role of TET1 mutations in ATC progression (vs. PTC/co-DTC) are not separately enumerated in the corpus PMID:38412093.
Sources
This page was processed by crosslinker on 2026-04-11. - PMID:28667006
This page was processed by wiki-cli on 2026-05-15.